盟科药业(688373.SH)：上半年净亏损1.39亿元

Core Viewpoint - Amgen Pharmaceuticals (688373.SH) reported a revenue of 66.97 million yuan for the first half of 2025, reflecting a year-on-year growth of 10.26% driven primarily by increased sales of its self-developed product, Contizolam Tablets [1] Financial Performance - The company achieved an operating income of 66.97 million yuan, which represents a 10.26% increase compared to the previous year [1] - The net profit attributable to shareholders of the listed company was -139 million yuan, indicating a loss [1] - Basic earnings per share were reported at -0.21 yuan [1]